About Venrock
Venrock is a venture capital firm founded in 1969. It is primarily based out of Palo Alto, United States. As of Oct 2026, Venrock is an active investor, having invested in 456 companies, with 16 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Series E round of Suki Overall, Venrock portfolio has seen 16 unicorns, 74 IPOs and 197 acquisitions including key companies like CloudFlare, athenahealth and Apple. A lot of funds co-invest with Venrock, with names like RA Capital Management sharing a substantial percentage of its portfolio. Venrock has team of 34 people including 16 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 9 more
Portfolio IPOs
Portfolio Unicorns
Venrock's List of Top Investments
Venrock has a portfolio of 456 companies, including 16 unicorns. Their most notable investments are in Angitia and Misty Robotics.Their portfolio spans across United States, Canada, United Kingdom and 13 more locations. They have invested in Life Sciences, Enterprise Applications, High Tech and 34 other sectors, across stages such as Series A, Series B and 9 more. Here is the list of top investments by Venrock:1. CloudFlare
Provider of cloud services for security, performance, and application development. The company delivers networking, security, and performance services through its connectivity cloud platform. It offers solutions for application security, application performance, and network services. The company's platform supports businesses in modernizing networks, securing workspaces, and optimizing web experiences.
Key facts about CloudFlare
- Founded Year: 2009
- Location: San Francisco (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $332M
- Employee Count: 7,330 as on Sep 30, 2026
- Investors: HTIF, Fidelity Investments and 17 Others
- Latest Funding Round: Post IPO, Aug 2021, $*****
- Highlight: Public
2. athenahealth
Cloud-based administrative tool for healthcare providers. The company has developed EHR, practice management, and population health solutions. The features include EHR, practice management, revenue cycle management (RCM), patient engagement, population health services, care coordination, clinical decision support, and more.
Key facts about athenahealth
- Founded Year: 1997
- Location: Watertown (United States)
- Annual Revenue: $1B+ as on Dec 31, 2017
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $49.1M
- Employee Count: 9,038 as on Jul 31, 2026
- Investors: Ares Capital Corporation, Cardinal Partners and 13 Others
- Latest Funding Round: Series B, Apr 27, 2004, $*****
- Highlight: Acquired
3. Apple
Technology company and product innovator developing consumer electronics. The firm designs smartphones, personal computers, tablets, wearables, and related hardware alongside proprietary operating systems and productivity applications. It provides integrated ecosystems including cloud computing, digital media distribution, payment processing, and enterprise software solutions. Services encompass content streaming platforms, mobile app marketplaces, augmented reality frameworks, and professional creative software suites. Continuous platform evolution maintains seamless hardware-software integration across personal computing and professional segments.
Key facts about Apple
- Founded Year: 1976
- Location: Cupertino (United States)
- Annual Revenue: $1B+ as on Sep 30, 2025
- Stage: Public
- Employee Count: 220,950 as on Sep 30, 2026
- Investors: 2020 Ventures, Berkshire Hathaway and 40 Others
- Latest Funding Round: Post IPO, Dec 25, 2020, $*****
- Highlight: Public
4. Gilead
Gilead is a developer of medicines to treat HIV/AIDS, liver diseases, cancer & others. It is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. It has developed many medicines such as Lenacapavir capsid inhibitor (GS-6207) for HIV, Long-acting treatment: 2 bNAbs (GS-5423, GS-2872), Selgantolimod TLR-8 agonist (GS-9688), PD-L1 inhibitor (GS-4224) HBV cure, and many more. In 2022, the company recorded annual revenues of $27.28B and a net profit of $4.59B.
Key facts about Gilead
- Founded Year: 1987
- Location: Foster City (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Last Known Valuation: $*****
- Stage: Acquired
- Employee Count: 14,855 as on Sep 30, 2026
- Investors: BB Biotech, Jindal Ventures and 18 Others
- Latest Funding Round: Post IPO, Jan 27, 2025, $*****
- Highlight: Acquired
5. Crunchyroll
Subscription-based anime streaming platform. It allows users to stream content under various categories, including anime series, shows, manga, drama, music, electronic entertainment, and more in various languages on multiple devices.
Key facts about Crunchyroll
- Founded Year: 2006
- Location: San Francisco (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $55.5M
- Employee Count: 547 as on Sep 30, 2026
- Investors: Venrock and TV TOKYO
- Latest Funding Round: Series B, Aug 26, 2015, $*****
- Highlight: Acquired
Venrock's Year-on-Year Investment Trends
Venrock has invested in 456 companies over the last 50 years, with an average of 12 new investments annually in the last 10 years. In 2025, it made 20 investments, while as of Oct 2026, it has made 19 investments in this year. Its most recent first time investment was in KymaThera and most recent follow-on round was in Suki.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 13 | 6 | 19 |
2025 | 13 | 7 | 20 |
2024 | 13 | 5 | 18 |
2023 | 10 | 5 | 15 |
2022 | 16 | 5 | 21 |
2021 | 11 | 13 | 24 |
2020 | 13 | 10 | 23 |
2019 | 11 | 13 | 24 |
2018 | 14 | 14 | 28 |
2017 | 9 | 13 | 22 |
Venrock's Investments by Stage
Venrock has made 116 investments in Series A stage with an average round size of $21.5M, 83 investments in Series B stage with an average round size of $38.5M and 43 investments in Series C stage with an average round size of $65.3M.Stage of entry | No. of Investments |
|---|---|
Series A | 116 |
Series B | 83 |
Series C | 43 |
Seed | 39 |
Post IPO | 29 |
Others | 42 |
Note: We have considered here, only first round of investments
Venrock's Investments by Sector
Venrock has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, Enterprise Infrastructure, High Tech and Consumer. Notably, it has invested in 361 Tech companies, 336 Enterprise (B2B) companies, 159 Software companies and at least 71 companies focusing on Saas.Sector | No. of Investments |
|---|---|
Life Sciences | 140 |
Enterprise Applications | 115 |
Enterprise Infrastructure | 42 |
High Tech | 42 |
Consumer | 29 |
Others | 240 |
Note: We have considered here, only first round of investments
Venrock's Investments by Geography
Venrock has made most investments in United States (320), followed by Canada where it has made 7 investments.Country | No. of Investments |
|---|---|
United States | 320 |
Canada | 7 |
United Kingdom | 6 |
China | 5 |
Israel | 4 |
Others | 10 |
Note: We have considered here, only first round of investments
Venrock's recent investments
Venrock has made 19 investments in 2026 so far. Suki and KymaThera are the latest among them.Here are the most recent investments by Venrock:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Oct 13, 2026 | United States | Series E | 8219 | [+6] | |
Oct 06, 2026 | United States | Series B | 3637 | [+2] | |
Sep 10, 2026 | United States | Post IPO | 9987 | [+15] | |
Sep 09, 2026 | United States | Series F | 5600 | [+10] | |
Aug 14, 2026 | United States | Series A | 1771 | - |
Unicorns in Venrock's Portfolio
Venrock has 16 unicorns in its portfolio - SkyRyse, Element Biosciences, ABL Space Systems and others. The most recent unicorn in their portfolio is SkyRyse. It became a unicorn in 2026, 7 years after Venrock first invested in it.Here is a list of unicorns in Venrock's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
61 | Developer of advanced flight automation systems for aircraft | 2016 | - | Hayward | Series C | twyfked | |
66 | Developer of benchtop DNA sequencer for research applications | 2017 | San Diego | Series E | avcdhrz | ||
49 | Developer of containerized launch system and small satellite launch vehicle | 2017 | El Segundo | Series B | pzgapz{ | ||
46 | Provider of AI and ML-based intelligence systems | 2019 | Washington | Series B | {yxv{wm | ||
65 | Provider of tech-heavy clinics for multiple healthcare solutions for patients | 2017 | Brooklyn | Series E | adtxseh |
IPOs and Publicly Listed companies in Venrock's Portfolio
74 of Venrock's portfolio companies have become public. ADARx Pharmaceuticals got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Sep 2026 at marketcap of $1.74B and Korsana got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are Venrock's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 25, 2026 | Aug 02, 2023 | Series C | 9992 | |
Sep 09, 2026 | Sep 10, 2026 | Post IPO | 7674 | |
Jul 19, 2024 | Feb 22, 2021 | Series B | 6994 | |
Feb 02, 2024 | Mar 16, 2026 | Post IPO | 8768 | |
Sep 12, 2023 | Apr 19, 2022 | Series A | 1344 |
Acquired companies in Venrock's Portfolio
197 companies from Venrock's portfolio have been acquired. The most recent acquisition was Smartling in Sep 2026 by Vitruvian Partners for $*****.Here are Venrock's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 15, 2026 | Mar 18, 2010 | Series A | 1771 | |
Aug 28, 2026 | - | - | 8426 | |
Aug 26, 2026 | Nov 25, 2019 | Series A | 3239 | |
Jul 22, 2026 | Jul 06, 2015 | Series B | 6191 | |
Jun 22, 2026 | Dec 07, 2022 | Series B | 7360 |
Team profile of Venrock
Venrock has a team of 34 members including 16 Partners and 11 Principals located in United States. Venrock's team sits on the board of 5 companies.Here is a list of top team members in Venrock:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Palo Alto | Devoted Health, Stride Health and 3 more | ||
Partner | Palo Alto | - | ||
Partner | New York City | - | ||
Partner | Palo Alto | - | ||
Partner | New York City | - | ||
Partner | San Francisco | - | ||
Partner | New York City | - | - | |
Partner | San Francisco | - | - | |
Partner | San Francisco | - | - | |
Partner | Palo Alto | - | ||
Partner | Mountain View | - | - |
Co-investors of Venrock
Over the past 50 years, 2067 investors have co-invested in Venrock's portfolio companies. This includes funds and angels.
- Invested before Venrock: RA Capital Management, HHS and 546 others have invested in rounds before Venrock. There are 10 companies where RA Capital Management has invested before Venrock and 9 companies where HHS has invested before Venrock.
- Top Co-investors of Venrock: 663 investors entered a company along with Venrock. These include investors like RA Capital Management (23 companies).
- Invested after Venrock: A total of 856 investors have invested in Venrock's portfolio after their investments. Top Investors include Fidelity Investments (14 companies), SVB (13 companies) and Hercules Capital (9 companies).
Recent News related to Venrock
•
Aligned Marketplace Raises $20M to Scale Independent Primary CareHIT Consultant•Aug 13, 2026•Venrock, Aligned Marketplace
•
Arca Raises $64 Million to Revolutionize and Humanize Wealth Management at ScaleGlobal Fintech Series•Jun 26, 2026•Venrock, Index Ventures, General Catalyst, Arca and 2 others
•
cAMPfield harvests $180M series A to advance oral IBD drug licensed from NewsoaraFierce Biotech•Jun 18, 2026•Campfield Care, Novo Holdings, Venrock, Abingworth and 2 others
•
Artiva lines up $300M as biotech stock sale prices at $11.52Stocktitan•May 08, 2026•Caligan Partners, Venrock, Adage Capital Management, RA Capital Management and 7 others
•
CellCentric raises $220 million for blood cancer drug trialspharmaphorum•May 06, 2026•CellCentric, Venrock
•
•
Adcendo ApS Completes $75 Million Series C FinancingCNW•Apr 14, 2026•Jeito, Bpifrance, Danmarks Eksport og Investeringsfond, Adcendo and 12 others
•
Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseaseshttps://www.intelligence360.news/•Mar 12, 2026•Korsana, Fairmount Ventures, J.P. Morgan Asset Management, TCG Crossover and 5 others
•
•
Angitia Biopharmaceuticals Secures $130M Series D for Musculoskeletal Drug PipelineEndpoints•Feb 05, 2026•Angitia, Frazier Life Sciences, Venrock
